KR101540004B1 - Composition of Health Functional Foods for Improving of Blood sugar, Blood pressure, Blood Circulation and Cholesterol into Blood - Google Patents

Abstract

The present invention relates to a dietary supplement composition for improving blood sugar, blood pressure and cholesterol including red yeast rice, coenzyme Q10, extracts of ginkgo leaf and extracts of Lagerstroemia speciosa leaf wherein the dietary supplement composition can additionally have sugar alcohol, thereby having outstanding effects of improving blood flow and liver function. In the present invention, the dietary supplement composition made from the red yeast rice, coenzyme Q10, extracts of ginkgo leaf and Lagerstroemia speciosa leaf and sugar alcohol is mixed with excipient and is accordingly made in a tablet or formulation, thereby enabling people to easily carry and take the same.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a health functional food composition for improving blood glucose, blood pressure, blood flow and cholesterol,

The present invention relates to a health functional food composition for improving blood glucose, blood pressure, blood flow and cholesterol, and a method for producing the same. More specifically, it can be used to improve blood cholesterol, red ginseng, antioxidant and coenzyme Q10 to help reduce high blood pressure, ginkgo biloba extract that can help improve memory and blood circulation, and postprandial blood sugar Blood pressure, blood flow, and cholesterol, which are composed of four components of a barna leaf extract that can help suppress blood pressure, blood pressure, and cholesterol. In addition to these four components, sugar alcohols may be further included.

These ingredients are health functional foods designated as high-end products by KFDA. The present invention provides an excellent effect for improving blood glucose, blood pressure, blood flow and cholesterol as well as improvement of liver function by mixing these four components. In addition, the composition mixed with these four ingredients may be mixed with an excipient to make a pill or a tablet to facilitate carrying and ingestion.

In recent years, metabolic syndrome, a chronic disease such as obesity, heart disease, diabetes and hypertension, has been increasing in developed countries due to changes in eating habits. Metabolic syndrome is a chronic metabolic disorder that causes multiple diseases, such as impaired glucose tolerance, hypertension, hyperlipidemia, obesity, and cardiovascular atherosclerosis, all appearing in the same individual. In other words, it is revealed that insulin is not made properly or plays a role in diabetes, hypertension, stroke, heart disease and various adult diseases when it breaks down glucose and sends it to liver and muscle. Diabetes mellitus is one of the rapidly increasing diseases in recent years, which is a chronic disease in which glucose is excreted in the urine due to abnormally high glucose concentration in the blood due to the relative insufficiency of insulin. That is, the carbohydrate in the digestive tract is decomposed by the digestive enzymes α-amylase and α-glucosidase, and is finally decomposed into glucose and fructose in the small intestine.

In the prior art related to the present invention, Korean Patent Registration No. 10-0873059 (use of inhibiting the fat accumulation of beta-glucan) relates to the use of beta-glucan for the prevention of obesity treatment. Beta glucan is used not only for weight loss but also for reduction of body fat, And leptin degradation. Korean Patent Registration No. 10-1421284 (a composition for improving constipation and a method for producing the same) is selected from the group consisting of kelp, azalea, reptilia, yulmu, thistle, germinated brown rice, rice germ, mushroom mycelium cultured brown rice, flower apple and dandelion Which is prepared by fermenting a composition with a lactic acid bacterium. Korean Patent Registration No. 10-0897613 (a functional oil containing fucoserol that has improved fluidity and blood lipid composition of blood), including fucoserol-solubilized fucosterol oil and fat, The present invention relates to a functional oil containing fucosterol, which is effective for improving blood lipid composition and has an effect of improving blood flow and improving blood fluidity and blood lipid composition which can be used for prevention and treatment of hyperlipemia. Korean Patent Registration No. 10-1155145 (a composition for improving blood flow, a method for producing the same, and a health functional food containing the same) includes a fraction having a molecular weight of 100,000 dalton or less isolated from an enzyme degradation product obtained by decomposing an acid drug into a protease. Korean Patent Registration No. 10-0996463 (a microorganism having an effect of inhibiting the rise of blood sugar and an effect of improving liver function and a food containing the microorganism) is characterized by comprising a microorganism preparation containing a microorganism belonging to the genus Bacillus, a method of producing a microorganism preparation containing the microorganism, A food containing the microorganism, and a method of producing the food containing the microorganism.

However, these are different in the technical composition from the present invention.

Red ginseng helps to improve blood cholesterol, Coenzyme Q10 to help reduce antioxidant and high blood pressure, Ginkgo biloba extract to help improve memory and blood circulation, Blood pressure, blood flow, and cholesterol, which are composed of four components, namely, a barberry leaf extract,

However, these four ingredients are individually effective in improving blood cholesterol, reducing antioxidant and high blood pressure, improving memory and helping to improve blood circulation, and helping to inhibit postprandial hyperglycemia. However, they are still widely used for blood pressure, blood glucose, blood flow and cholesterol There is no health functional raw material.

Blood sugar is the glucose contained in the blood, and the blood sugar supplied to the human body with the help of insulin enters the cell and produces the energy necessary to maintain the normal function. In normal people, after a meal, blood glucose temporarily goes up and then goes down to normal level again by insulin. However, if the insulin secretion is abnormal in the pancreas, or if the insulin secretion does not work, glucose is used as energy in the body I can not get out. If the blood sugar level is higher than normal, it may interfere with the movement of the regulated substance transported through the blood, lower the function of the red blood cells and the white blood cells, and impose a burden on the kidney. Therefore, blood glucose must always be maintained at a certain level so that the energy of the body can be supplied smoothly.

Blood pressure refers to the force applied by the blood flowing into the blood vessel to the blood vessel wall, which refers to the pressure of the blood flowing in the arterial blood vessel, and is expressed by the systolic (maximum) blood pressure and the diastolic (minimum) blood pressure. The blood pressure control is a function to keep the blood pressure constant in the body. As the blood pressure increases, the cardiac output decreases in the heart. In the kidney, the sodium amount decreases and the blood amount decreases. Thus, the amount of blood flowing through the blood vessel decreases, The blood pressure is lower than the normal level. On the contrary, when blood pressure is lowered, the blood volume increases in the heart and kidney, and the blood pressure is maintained at a certain level. However, when the wall of the blood vessel is narrowed or damaged, the elasticity of the blood vessel decreases and the blood pressure becomes high and hypertension is known as a cause of heart attack or stroke. Therefore, the regulation of blood pressure in our body is an important function to maintain a constant blood pressure.

Angiotensin converting enzyme is an enzyme that converts angiotencin I into physiologically active angiotencin II and suppresses the decomposition of bradykinin, which is most important for blood pressure control. Thereby suppressing an increase in blood pressure.

Inhibition of blood glucose elevation ultimately converts monosaccharides to saccharides in which? -Glucosidase is degraded by? -Amylase. Such inhibition of enzyme activity is very useful for the treatment of carbohydrate-related diseases such as type 2 diabetes, by delaying carbohydrate hydrolysis and absorption and limiting postprandial glucose concentration.

It is known that the extracts of Barnaby Leaf, Hongkuk, Coenzyme Q10 and Ginkgo biloba extract of the present invention are effective in improving blood circulation, reducing blood pressure, decreasing blood pressure and / or suppressing cholesterol, respectively, in dietary supplements.

Blood flow maintains blood flow homeostasis of plasma and blood cells constituting blood and maintains normal function of human body by maintaining normal hemostasis and protection function in injured area of blood vessel or inflammation site. However, excessive activation of coagulation factors in the plasma, promotion of platelet aggregation, and erythrocyte deformity break down the homeostasis of blood flow, resulting in cardiovascular diseases such as arteriosclerosis and stroke. The endothelial cells of the blood vessels are substances that break down blood clots and are an important part of regulating blood flow and velocity. When this endothelial cell is damaged by some stimulus, cholesterol builds up in it and forms a plaque. The portion of the blood vessel where the plaque is piled up swells, and the blood vessel narrows, which may interfere with the flow of blood. The blood flow is closely related to blood cholesterol, fat and glucose, so reducing intake of animal fat and salt, and increasing the intake of vegetables, fruits, fish, and grains can help the flow of blood.

3-hydroxy-3-methylglutaryl) -COA reductase is an important enzyme for cholesterol biosynthesis. It is used for the treatment of atherosclerosis with statin These drugs are used as inhibitors of HMG-CoA reductase. Therefore, it is known that the activity of HMG-CoA reductase is regulated to regulate blood cholesterol level to improve blood circulation. In addition, nitrogen monoxide (NO) is a very important messenger molecule involved in nervous system, immune system, cardiovascular system, etc. in relaxing blood vessels. NO stimulates endothelium-dependent vasorelaxation by stimulating guanylate cyclase (GC) in vascular smooth muscle cells to increase 3 ', 5'-cyclic guanosine monophosphate (cGMP). sodium nitroprusside acts as a vasodilator by stimulating smooth muscle guanylate cyclase to increase the production of cGMP.

Liver is a vital organs responsible for protein synthesis and glucose metabolism, carbohydrate metabolism, nucleic acid metabolism, lipid metabolism, and drug metabolism in living organisms and is one of the essential organs for maintaining life. Liver function is deteriorated and hepatitis, sarcoidosis, fatty liver, alcoholic liver disease, liver cancer, liver cirrhosis, pregnancy addiction, non-Hodgkin's lymphoma, Wilson's disease, Reye's syndrome, other neonatal jaundice, hepatomegaly, liver abscess, Liver cirrhosis, liver cirrhosis, etc., such as mental stress and smoking due to heavy damage to the liver damage to the immune system, causing abnormalities and may cause other diseases.

The major liver function tests, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), are enzymes present in hepatocytes, which are released into the blood and increase in blood levels when hepatocytes are damaged. ALP (alkaline phosphatase) is an enzyme present in the hepatocyte (bile duct) in the hepatocytes, and it is rapidly elevated mainly in the bile excretion disorder. GGT (gamma (γ) -glutamyl transferase) is an enzyme present in hepatocytes (bile ducts) used in hepatocytes and is used to determine bile-acid excretion disorders with ALP. Bilirubin is a metabolite of heme, an iron-binding element. When bilirubin is produced in spleen, it is transferred to the liver. It is converted into bile in hepatocytes, stored in the gallbladder, and then released into the duodenum. Increase in bilirubin production (hemolysis), hepatocyte metabolism disorder, bile (bile) excretion disorders (cholelithiasis, cholangitis) increases the blood level of bilirubin. Other liver function tests include total protein, albumin, lactate dehydrogenase (LDH), and ammonia.

Blood triglycerides help to lower LDL cholesterol and improve the breakdown of good high density lipoprotein (HDL) cholesterol, which increases the risk of atherosclerosis. Serum triglycerides are the most abundant fat in the blood, in the form of fat in the blood coming from the fat coming from the diet or synthesized in the liver. Normal triglyceride levels are below 150 mg / dl.

Sugar alcohol is a natural carbohydrate, also known as polyols (sugar alcohols such as glycerol, sorbitol, and inositol), but does not contain sugar or alcohol. The sugar alcohols used in foods are maltitol, sorbitol, reduced starch syrup, lactitol, mannitol, and the like, although sugar alcohols are used as substitutes for sugar because they have little calories and digestion and absorption. , Paratinitol, and erythritol. Sugar, glucose, fructose, sugar, sugar, glucose and fructose, such as slow, because it is almost digestible in the small intestine, blood sugar and insulin does not raise the diabetes is good for patients. The sugar alcohols are widely used for sword because of the sensation of refreshing due to endothermic and hydration, and cavities in the mouth. Due to these properties, sugar alcohols are dissolved in the body together with the composition of the present invention, and it is expected that the gastrointestinal or small intestine facilitates the peritoneal action of the intestines to smooth the bowel movements.

The present invention has been accomplished based on the discovery that there is an excellent effect for improving blood glucose, blood pressure, blood flow and cholesterol, as well as improving liver function, by mixing these four raw materials.

The present invention is a composition comprising Hongkuk, Coenzyme Q10, Ginkgo biloba extract, and Barnaby extract. The composition is excellent in blood glucose lowering, blood pressure reduction, blood circulation improvement, cholesterol reduction and liver function improvement.

(1) Functional content: It can help to improve cholesterol in the blood. (2) Total amount of monacolin K contained in daily intake: 0.5mg / g or more. Respectively. (3) Indicator component: Total mono-choline k should be at least 0.5 mg / g, and active mono-choline k should be identified.

Coenzyme Q10 (1) Functional content: It can help antioxidant and high blood pressure reduction. (2) Daily intake: coenzyme Q10 which is contained more than 980mg / g. (3) Indicator component: Coenzyme Q10 should be contained at 980mg / g or more.

(2) Flavonol glycosides containing 240 ~ 300mg / g of daily intake: 28 ~ 36mg (3) Notes on ingestion: Pregnant women , Lactating women, children, and before and after surgery are cautioned about ingestion (anticoagulant). (4) Indicator component: Flavonol glycosides should be contained in the amount of 240 to 300 mg / g, and the ratio of quercetin to chemperol should be 0.8 to 1.2.

(1) Functional content: It can help suppress postprandial hyperglycemia. (2) It is 0.45 ~ 1.3mg as corosolic acid containing 9 ~ 13mg / g of daily intake. (3) Indicator component: It should contain 9 to 13 mg / g as corosolic acid.

The present invention relates to a method of preparing a composition by mixing the above-mentioned four health functional foods such as Hongkuk, Coenzyme Q10, Ginkgo biloba extract and Barnaby leaf extract to provide a composition for improving liver function in addition to blood glucose lowering, blood pressure lowering, blood flow improvement and cholesterol lowering I have to. In addition, sugar alcohols may be included in the composition.

The present invention is intended to demonstrate the following: 1) reduced blood sugar; 2) reduced blood pressure; 3) improved blood flow; 4) reduced cholesterol; and 5) improved liver function. For this purpose, the effect of cholesterol reduction on the efficacy of the composition containing the four components will be examined.

≪ Experimental Example 1 > Cholesterol formation inhibitory effect

HepG2 cells were cultured in 6 wells at 3 × 10 ⁵ cells / ㎖ for 24 hrs. Then, glucose, coenzyme Q10, ginkgo biloba extract and banaba leaf extract were mixed with sugar alcohols Gt; < / RTI > After 24 hours, the cell culture was concentrated using centrifucal filter units (Vivaspin 4, Sartorius stedium, Goettingen, Germany). The total amount of cholesterol was measured using a cholesterol ester quantitation kit (BioVision, Mountain View, Calif., USA). After incubation at 37 ° C for 1 hour, the absorbance was measured at 530/590 nm with a microplate reader (Synergy HT, Bio-Tek, USA).

The effect of inhibiting the cholesterol formation of 1 (Hongkuk), 2 (Hongkuk + Coenzyme Q10), 3 (Hongkuk + Coenzyme Q10 + Ginkgo biloba extract) and 4 (Hongkuk + Coenzyme Q10 + Ginkgo biloba extract + (Non) 1 to 12, hepatocyte-derived HepG2 cells were used to compare the effect of inhibiting cholesterol formation. The results are shown in Table 1.

Cholesterol production inhibitory effect (unit: mg, g) division Experimental Example (Composition) One 2 3 4 5 6 7 8 9 10 11 12 13 14 15 One Hongkuk 3 7 12 - - - - - - - - - - - - 2 Hongkuk - - - 10 6 4 - - - - - - - - - CoQ ₁₀ - - - 50 100 200 - - - - - - - - - 3 Hongkuk - - - - - - 3 6 9 - - - - - - CoQ ₁₀ - - - - - - 180 150 100 - - - - - - Ginkgo leaf - - - - - - 20 35 50 - - - - - - 4 Hongkuk - - - - - - - - - 8 7 6 - - - CoQ ₁₀ - - - - - - - - - 50 120 190 - - - Ginkgo leaf - - - - - - - - - 50 35 20 - - - Barnabas - - - - - - - - - 2 One 0.3 - - - 5 Hongkuk - - - - - - - - - - - - 3 7 12 CoQ ₁₀ - - - - - - - - - - - - 200 100 50 Ginkgo leaf - - - - - - - - - - - - 20 35 50 Barnabas - - - - - - - - - - - - 2 One 0.3 Sugar alcohols - - - - - - - - - - - - 5 3 One Anticholesterol effect 16 18 20 30 27 24 26 30 40 56 55 54 57 58 59

(Glycine + Coenzyme Q10, Hongkuk + Coenzyme Q10 + Ginkgo biloba extract, Hongkuk + Coenzyme Q10 + Ginkgo biloba extract + Barnaby leaf extract, Hongkuk + Coenzyme Q10 + Ginkgo biloba extract + Barnabas extract) The combination of coenzyme Q10, Ginkgo biloba leaf extract and Barnaby leaf extract showed better inhibitory effect on cholesterol formation (Composition ratio 4>3>2> 1) than leaf extract + sugar alcohols group The higher the amount of these additives, the better the effect of inhibiting cholesterol formation. In addition, these four compositions showed slight cholesterol inhibitory effect in the group (sugar composition 5) supplemented with sugar alcohols. Therefore, the compositions of compositions 13, 14 and 15, which had a good cholesterol-inhibiting effect, were applied to the following experiment. (Mg, CoQ ₁₀ ; mg, ginkgo biloba extract, mg, banaba leaf extract, mg, sugar alcohols, g)

≪ Example 1 > Change in cholesterol content of the composition

Experimental animals were purchased from Sprague-Dawley rats at 4 weeks of age (Orient Bio Seongnam) and fed a diet of solid feed (CJ) for 1 week. A randomized block design with an average body weight of 134 ~ 138g was divided into 4 groups of 8 rats per each treatment group and one rats were separated in a stainless steel cage.

11.7% of dietary total calories were fed to the diet by the normal diet group (AIN-93). In the high fat diet group, 40% of the total calories were fed to the fat by high fat diet using beef tallow as fat source.

The animals were fed normal diet and high fat diets for 4 weeks to 10 weeks of age from the experimental animals. The diets containing 13%, 15%, and 15% A diet was provided to observe the effect. Experimental animals were separated and fed one by one without water and diet.

Blood was collected at the sacrifice of the heart, and then centrifuged at 3000 rpm for 15 minutes to obtain serum. These samples were stored at -70 ° C until analysis. The total fat content of serum was measured by colorimetric method by Frings method and the content of cholesterol and triglyceride was measured by enzyme colorimetric method using kit (Sigma USA). LDL and VLDL were precipitated with dextran sulfate and MgCl ₂ as precipitation reagents, and the cholesterol content of the supernatant was quantitated using a kit (Sigma, USA).

Changes in blood cholesterol and triglyceride content (mg / dl) division Total cholesterol  HDL cholesterol Experimental Example 13 Experimental Example 14 Experimental Example 15 Experimental Example 13 Experimental Example 14 Experimental Example 15 Normal diet 59.2 58.8 60.2 44.3 45.2 48.7 Highland method 74.4 73.9 71.2 45.2 44.8 45.6 Composition 1% 68.5 69.2 67.6 56.4 55.8 55.6 Composition 5% 67.3 66.4 65.3 55.6 55.5 54.2 Composition 9% 65.2 63.4 62.8 55.1 54.6 53.4

Serum total cholesterol content did not differ between the experimental groups, but HDL cholesterol which lowered the blood cholesterol concentration was significantly increased in the composition dietary group than in the high fat control group. It is judged that sugar alcohols act to promote the movement and absorption of the composition into blood.

≪ Experimental Example 2 > Α-glucosidase inhibitory activity of the composition

Acarbose (GlucoBye, Korea Bayer) is an oral drug that inhibits the rapid rise of postprandial blood sugar in diabetic patients. It is known to lower the postprandial blood glucose level by inhibiting alpha glucosidase and delaying digestion and absorption of carbohydrates. To examine the alpha glucosidase inhibitory activity of the composition of the present invention, 1 mg / ml to 10 mg / ml of compositions 13, 14 and 15 obtained in Experimental Example and 1 mg / ml of acarbose (trade name: Glucoba, Korea Bayer) Of alpha-glucosidase inhibition was obtained as follows. A 96-well plate was prepared, and 50 쨉 l of each of the above samples was added in triplicate. At this time, 50 ㎕ of third distilled water was added to the control. The concentration of alpha glucosidase was adjusted to 1.0 U / mL in 0.1M phosphate buffer (pH 6.9), and 100 μL was taken and added to each sample. The treated 96-well plate was incubated at 25 [deg.] C for 10 minutes. After incubation, 50 μl of a 5 mM substrate solution of p-nitrophenyl-α-D-glucopyranoside was added to the sample to activate α-glucosidase activity. After incubation for 5, 10, 15, 20 and 30 minutes, the absorbance was measured using a 405-nm microarray reader. The inhibition rate of the alpha-glucosidase of the samples was quantified and measured using the following equation The results are shown in Table 2 below.

Inhibition rate (%) = ([OD.s.control] - [OD.s.test]) / [OD.s.control]

(In the formula 1, OD.s.control is the control absorbance value, and [OD.s.test] is the absorbance value of the sample)

Alpha glucosidase inhibition rate division Control group Composition 13 (mg / ml) Composition 14 (mg / ml) Composition 15 (mg / ml) % Inhibition One One 3 5 One 4 7 One 5 10 41.5 30.5 42.2 59.8 31.4 56.5 68.1 30.8 60.8 86.8

In the above, the control represents 1 mg / ml of acarbose. Referring to Table 1, it can be seen that the fermentation broth of the plant lactic acid bacteria according to the present invention exhibits high alpha glucosidase inhibitory activity.

≪ Example 2 > Measurement of insulin secretory activity

NIT-1 cells are normal pancreatic β-cells derived from mouse. They have the most similar mechanism to human pancreatic tissue, promote insulin secretion in proportion to glucose concentration, and have proinsulin gene as well as humans. It is thought to have similar conditions to humans and is known as a cell line suitable for studying the physiology of beta cells.

NIT-1 cells were seeded at 3 × 10 ⁵ cells / ㎖ in a 6-well plate and cultured for 36 hours. After the cells were completely removed from the cells, the cells were washed with Krebs-ringer buffer (pH 7.4) Glucose in the medium was completely removed, and 1 ml of this buffer was dispensed and pre-treated at 37 ° C for 1 hour. The cells were exposed to 2 mM glucose and 11 mM glucose to determine insulin secretion according to glucose concentration. The cells were exposed to 2.5 nM exendin-4 in the positive control, 10 μg / ml in the composition 13, 14 and 15, ㎍ / ㎖ and 100 ㎍ / ㎖, respectively, and the amount of secreted insulin was measured by using Ultra Sensitive Rat Insulin ELISA kit (Crystalchem, Inc., Downers Grove, IL) for 6 hours. The insulin secretory activity using NIT-1 cells was determined by measuring the effect of compositions 13, 14 and 15 on the insulin secretion ability of NIT-1 cells by extracting with ethanol under the conditions of 2 mM glucose and 11 mM glucose. As a result, insulin secretion . Increased insulin secretion was also observed in exendin-4 added as a positive control. On the other hand, the effects of the compositions 13, 14, and 15 on insulin secretion were measured, and the results are shown in Table 4 below. Most of them promoted insulin secretion in a concentration-dependent manner.

Insulin secretion activity measurement result division Control group Composition 13 Composition 14 Composition 15 Insulin fraction (%) 2 mM glucose 38.4 48.5 46.4 42.3 11 mM glucose 49.5 59.4 56.8 49.3

The composition showed a 10-20% increase in insulin fraction compared to the control.

≪ Example 3 > NO production assay &

NO, an indicator of blood flow improvement, is a very important messenger molecule involved in the cardiovascular system as well as the nervous system and immune system in the human body. NO is produced from L-arginine by Nitric oxide synthase (NOS), which is rapidly converted to NO ₂ ^- (NItrite) and NO ₃ ^- (Nitrate). Griess reagent (1% sulfanilamide in 5% phosphoric acid + 1% N - (1-naphthyl) ethylenediamine dihydrochloride) chemically reacts with nitrite to form a purple azo salt. Can be obtained by measuring the concentration of nitrite from the concentration of azo salt at 548 nm. HUVEC cells were diluted to a concentration of 1 × 10 ⁵ / ml in a 12-well culture dish and dispensed. After 24 hours, the compositions of the above compositions (Experimental Examples 13, 14, 15) were treated and cell culture was obtained after 24 hours. 150 μl each of the cell culture supernatant of the control (Ginkgo biloba extract; flavonol glycoside 35 mg) and the composition of the compositions (Experimental Examples 13, 14 and 15) was added, and then a mixture of 20 μl of griess reagent reagent and 130 μl of H ₂ O was added at room temperature For 30 min (Griess Reagent Kit for Nitrite Determination, Invitrogen). The absorbance of the reaction was then measured at 548 nm using a microplate reader (Bio-Tek, USA). The concentration of nitrite was calculated from the standard curve of nitrite.

Since the compositions (Experimental Examples 13, 14 and 15) were excellent in inhibiting cholesterol, NO production was confirmed by treating the four compositions at 100, 200, 300, 400, and 500 mg / g concentrations as shown in Table 4. As a result, NO production was higher in the group treated with the composition than the Ginkgo biloba extract.

NO generation effect division Treated group NO production rate (%) Ginkgo biloba extract Composition 13 Composition 14 Composition 15 98 - - - Addition amount
mg / g 100 - 177 191 225 200 - 291 328 386 300 - 421 467 493 400 - 592 618 631 500 - 581 602 625

Ginkgo biloba leaf extracts containing 100-500 mg / g of flavonol glycosides were used.

From the above results, the compositions (Experimental Examples 13, 14, and 15) showed significantly higher NO generation effect than the control group (ginkgo leaf extract).

≪ Example 4 > Antihypertensive activity effect

Angiotensin converting enzyme (ACE) acts as an important enzyme to regulate blood pressure by converting angiotensin Ⅰ to angiotensin Ⅱ. Antihypertensive activity was measured by the method of Cushman and Cheung (1971) as a measure of ACE inhibitory activity. That is, add 50 μl of ACE enzyme solution and 100 μl of sodium borate buffer (pH 8.3) to 50 μl of sample (extract of composition 10), and preincubate at 37 ° C for 5 minutes. Add 50 μl of Hippuryl-His-Leu solution (25 mg / 2.5 ml sodium borate buffer) as a substrate, react at 37 ° C for 30 minutes, and then 250 ml of 1N HCl is added to stop the reaction. For the control, 50 μl of distilled water was used instead of the sample solution, 250 ml of 1N HCl was added, and then 50 μl of the ACE enzyme solution was added. Add 1.5 ml of ethyl acetate, vortex for 15 seconds, and centrifuge at 3000 rpm for 5 minutes to take 1 ml of supernatant. The supernatant was completely dried, dissolved in 3 ml of distilled water, and the absorbance at 228 nm was measured as the ACE inhibition rate according to the following equation.

ACE inhibition rate (%) = (1-A / B) × 100, A: absorbance of the sample added, B: absorbance of the sample not added, A and B are the values excluding the absorbance of the control.

Table 6 shows that ACE protein expression was decreased in a concentration-dependent manner when the treatment amount of the sample was 100, 200 and 400 / / ml in the same manner.

ACE inhibitory activity division Control group Treatment group (占 퐂 / ml); Composition 10 50 100 200 400 ACE inhibitory activity 35.2 48.5 58.9 67.3 78.9

Example 5: Effect of improving liver function

<Improvement of liver function animal test>

The rats used in the present invention were 150 g ± 5 g of Sprague-Dawley rats and were housed in a stainless steel housing (temperature and humidity, temperature 22 ± 2 ° C., humidity 50 ± 5% Lt; / RTI &gt; After the first week of adaptation, the experimental diet was consumed for 5 weeks. Rats were divided into four groups, each of which was divided into 10 groups. The basal diet group (BDG) consisted of 23% starch, 22% wheat flour, 20% sugar, 2% corn oil, 4.5% woogie, 20% casein, 5% fiber, 1.5% mineral and 2% Respectively. 100 g parts by weight of the basic formula was added to 109.8 mg parts by weight of the composition of Experimental example 10 of the present invention, 100 g parts by weight of the basic formula was added to 229.8 parts by weight of the composition of Experimental example 13, 100 g parts by weight of the diet, and 112.4 parts by weight of the composition of Experimental Example 15 were mixed with 100 g parts by weight of the basic formula.

To collect the blood of the experimental animals, the animals were fasted for 16 hours at the end of the experiment. Anesthesia was performed to collect blood from the heart, 2 ml was taken from the CBC tube, and the remaining was centrifuged and serum was separated and stored at -80 ° C.

Serum total protein was determined by Biuret method using TP kit (total protein reagent) to form colored compounds and then the concentration was measured with an automatic analyzer. The albumin concentration was analyzed by an automatic analyzer after forming compounds using albumin kit by brocresol green-Doumas method. The total bilirubin was developed by kit (total bilirubin reagent) by azo reaction principle, Were measured.

Creatinine concentration was measured by an automatic analyzer using Creakit and the rate of formation of pocroted and colored compounds in alkaline solution. Uric acid concentration was measured by the PAP method and the concentration of uric acid was measured by an automatic analyzer. The concentration of blood urea nitrogen (BUN) was measured by urea kit and automatic analyzer according to kinetic UV test. The concentration of alkaline phosphate (ALP) was measured by IFCC method using kit and measured by automatic analyzer. The glutamic oxaloacetate transaminase (GOT) concentration, which determines liver function, is changed by GOT in the serum, and aspartic acid and a-ketoglutaric acid are changed to oxaloacetic acid and L-glutamic acid. Again, oxaloacetic acid produces malate by the action of MDH in the presence of coenzyme NADH. When NADH is oxidized to NAD, the concentration is determined by measuring the decrease of absorbance at 340 nm.

The concentration of glutamic pyruvate transaminase (GTP) was changed by the action of GTP in serum, and L-alanine and a-ketoglutaric acid were changed to pyruvic acid and L-glutamic acid. The pyruvate produced was lactate in the presence of the coenzyme NADH and lactate was produced. When the NADH was oxidized to NAD, the absorbance was measured at 340 nm and measured with an automatic analyzer using ALT kir. The concentration of lactate dehydrogenase (LDH) was determined by LDH kit using an automatic analyzer after incubation with buffered pyruvate substrate and NADH _{2. The} result was that pyruvic acid was reduced by LDH in the serum and lactate and NAD were produced . Table 7 summarizes the haematological characteristics and serum clinical chemistry to observe changes in health status after 5 weeks of fermentation with high fat diet.

Blood and serum test division BDG Experimental Example 10 Experimental Example 13 Experimental Example 14 Experimental Example 15 Total protein
(g / dl) 4.85 ± 0.21 4.82 ± 1.02 4.85 ± 0.15 4.85 ± 2.45 4.84 ± 2.15 Albumin (g / dl) 3.32 ± 0.12 3.42 ± 1.23 3.56 ± 3.12 3.55 ± 2.11 3.56 ± 1.42 Total bilirubin
(mg / dl) 0.18 ± 0.11 0.22 0.02 0.21 + 0.04 0.22 0.12 0.23 + 0.13 Creatine
(mg / dl) 0.58 ± 0.05 0.59 + 0.04 0.60 + - 0.12 0.61 + 0.145 0.61 + - 0.23 Uric acid (mg / dl) 1.75 + - 0.46 1.84 ± 0.23 1.94 + - 0.45 1.93 + - 0.51 1.94 + - 0.61 BUN (mg / dl) 12.04 + - 3.02 11.97 ± 3.23 11.75 ± 2.34 12.11 ± 2.57 11.56 ± 3.21 ALP (mg / dl) 108.36 ± 1.56 116.45 ± 3,27 126.54 + - 5.43 127.73 + - 4.35 128.39 + - 6.21 GOT (U / L) 30.10 ± 14.12 25.67 ± 2.03 23.57 ± 2.13 22.78 + - 4.12 22.13 + - 2.13 GPT (U / L) 27.23 + - 4.13 25.74 ± 3.12 23.58 + - 3.12 22.87 + - 4.25 23.24 + - 2.34 LDH (U / L) 139.56 ± 30.07 112.08 ± 20.21 109.46 ± 19.23 108.34 ± 18.23 107.54 + 16.34

As shown in Table 7, all of the compositions of Experimental Example 10, Experimental Example 13, Experimental Example 14 and Experimental Example 15 maintained the normal hematological characteristics as compared with the basic dietary group, and the composition did not exceed the normal level The extracts did not have any harmful effect on hematologic factors. In addition, it was shown that GOT, GPT, and LDH, which are indicators of liver function, are beneficial for improving liver function by feeding to experimental rats for 5 weeks.

<Clinical Trial of Liver Function Improvement>

The liver function improving composition prepared in the compositions 10, 13, 14, and 15 of the present invention was administered to 10 persons of 35-50 year old male and 10 patients with liver dysfunction three times a day for 3 days and 40 days, AST, ALT, γ-GTP and GOT were measured. The results are shown in Table 8 below. In general, their normal ranges are AST 5 to 40, ALT 10 to 40, γ-GTP 0 to 60, and GOT 0 to 40.

Liver function improvement effect division Before ingestion Composition 10 Composition 13 Composition 14 Composition 15 Three weeks Six weeks Three weeks Six weeks Three weeks Six weeks Three weeks Six weeks AST (U / L) 121 58 34 57 32 56 32 54 31 ALT (U / L) 89 56 32 56 31 55 31 54 30 γ-GTP (U / L) 91 46 34 45 33 44 32 42 31 GOT (U / L) 89 42 34 43 33 42 32 41 31

As described above, the compositions 10, 13, 14, and 15 of the present invention have an effect of improving liver function by significantly lowering the hepatic function index in patients with hepatic dysfunction after 3 and 6 weeks of administration of the composition.

<Application example>

Composition 13 of the present invention was mixed with an excipient acceptable as a health functional food product to make a pill, tablet, granule, health supplement and drink.

1) Manufacture of pills

After mixing 90 mg of the composition of the present invention, 5 mg of glutinous rice starch and 5 mg of purified water, 100 mg of a pellet was prepared according to a conventional method.

2) Preparation of tablets

3 g of the composition of the present invention, 0.1 g of corn starch, 0.11 g of milk sugar, and 2 mg of magnesium stearate were mixed and tableted according to a conventional preparation method.

3) Preparation of capsules

2.5 g of the composition of the present invention, 0.1 g of corn starch, 0.1 g of milk sugar and 2 mg of magnesium stearate were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

4) Preparation of granules

After mixing 4 g of the composition of the present invention, 50 mg of soybean extract, 200 mg of glucose and 600 mg of corn starch, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules and filled in the pellets.

5) Manufacture of beverages

1 g of the composition of the present invention, 0.1 g of citric acid, 100 g of fructooligosaccharide, and 900 g of purified water were mixed and stirred, heated, filtered, sterilized and refrigerated to prepare a drink.

6) Manufacture of health supplements

20 g of the composition of the present invention, a proper amount of vitamin mixture, 70 ㎍ of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.2 mg of vitamin B6, 0.2 mg of vitamin B12, 10 mg of vitamin C, Nicotinic acid amide 1.7 mg, folic acid 50,, calcium pantothenate 0.5 mg, inorganic mixture suitable amount, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium phosphate monobasic 15 mg, dibasic calcium phosphate 55 mg, citric acid 90 mg of potassium, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride were mixed to prepare granules. However, the formulations can be modified in various ways depending on the application.

The composition of the present invention is industrially applicable because it is effective in improving liver function in addition to blood glucose lowering, blood pressure lowering, blood circulation improvement and cholesterol lowering.

Claims (6)

A health functional food composition for improving blood pressure and blood flow comprising 12 mg of red yeast, 50 mg of coenzyme Q 10, 50 mg of ginkgo leaf extract, 0.3 mg of banaba leaf extract and 1 mg of sugar alcohols delete delete The health functional food composition for improving blood pressure and blood flow according to claim 1, wherein the sugar alcohols are any one or more selected from maltitol, sorbitol, reduced syrup, lactitol, mannitol, parathinitol and erythritol A health functional food made from the health functional food composition for improving blood pressure and blood flow according to any one of claims 1 to 4 6. The method according to claim 5, wherein the formulation is selected from the group consisting of pills, tablets and granules.